Portfolio of Studies

Lakeside Healthcare Research and Innovation Unit

• Anthos Therapeutics Lilac TIMI 76 - A study to evaluate the efficacy and safety of Abelacimab in high-risk patients with atrial fibrillation, who have been deemed unsuitable for oral anticoagulation. 
• Amgen Vesalius CV Study -  A study looking at the efficacy of the drug Evolocumab (Repatha) is at lowering LDL-C in patients at risk of having a cardiovascular event.
• AstraZeneca LOGOS study - An asthma study looking at the effectiveness of new combined triple therapy inhaler in patients with inadequately controlled asthma.
• AstraZeneca Titania: A Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Tozorakimab in participants with symptomatic chronic obstructive pulmonary disease (COPD) and a history of COPD exacerbations.
• AZ Bax24 - A randomised, double-blind, placebo-controlled, parallel group study to assess the effect of Baxdrostat on ambulatory blood pressure in participants with resistant hypertension. 
• Bayer Alpine 1 - A study to learn about how well BAY3283142 works and its safety in participants with chronic kidney disease.
• Boehringer Ingelheim 0022 CKD Study - A study for chronic kidney disease looking at a new therapy to improve kidney function.
• George Medicines GMRx2 - A clinical trial called GMRx2, single pill containing three widely used blood lowering drugs. Testing the efficacy and safety of GMRx2 compared to placebo for the treatment of hypertension.
• GSK COPD PAS - A study looking at safety cardiovascular outcome data for two inhalers used in the management of COPD.
• GSK RSV 006 - A vaccine study looking at the efficacy of a RSV (Respiratory Syncytial Virus) vaccine within older adults living in the community in preventing RSV infection.
• GSK Low Carbon Asthma - A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via Metered Dose Inhaler (MDI) containing propellant HFA-152a or HFA-134a in participants ≥18 years of age with asthma. 
• GSK RSV 0A=ADJ-012 - An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adults 60 years of age and above who participated in RSV OA=ADJ-006 study. 
• Novavax 2019nCoV-302 - A vaccine study looking at the efficacy of the Novavax Covid-19 vaccine in adults in preventing serious Covid-19 Illness.
• Leo Pharma Adjust - Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight. 
• Moderna CMVibe - A Phase 1/2a study for a Cytomegalovirus (CMV) vaccine in adult and paediatric participants. 
• Moderna Fluent - A Phase 3, randomized, observer-blind, active-controlled, case driven study to investigate the safety, efficacy, and immunogenicity of mRNA-1010 candidate seasonal influenza vaccine compared with a licensed inactivated seasonal influenza vaccine in adults ≥50 Years of age. 
• Moderna Mpower mPox - A clinical trial of an investigational mpox vaccine, mRNA-1769-P101 for adults ages 18-C49.
• Moderna NextCove - A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety and immunogenicity and relative vaccine efficacy of mRNA-1283.222 administered as a booster dose compared with mRNA1273.222 in participants aged 12 years and older for the prevention of COVID-19.
• Pfizer BHV3000-406 - A Phase 4, randomized, double-blind, placebo-controlled, efficacy and tolerability trial of Rimegepant for the acute treatment of migraine in adults unsuitable for Triptan use. 
• Pfizer BHV3000-407 - A Phase 4, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of Rimegepant for the prevention of migraine in adults with a history of inadequate response to oral preventive medications. 
• Valneva VLA2001-301 - A vaccine study looking at the efficacy of the Valneva Covid-19 vaccine in adults in preventing serious Covid-19 illness.